Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21937490 | 0.97 | ALDH1A1 (0.35) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21937494 | 0.97 | ALDH1A1 (0.35) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL24088291 | 0.96 | ALDH1A1 (0.33) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21936428 | 0.94 | ALDH1A1 (0.38) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL24088442 | 0.94 | ALDH1A1 (0.38) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21937514 | 0.94 | ALDH1A1 (0.38) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21936453 | 0.94 | ALDH1A1 (0.38) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21937515 | 0.92 | ALDH1A1 (0.36) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21936986 | 0.92 | GPR3 (0.38) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21936426 | 0.91 | MAPT (0.41) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380568-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD (KR) | 2021-12-09 | — | — | US | disclosed |
| WO-2020085797-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREOF | 덕산네오룩스 주식회사 | 2020-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380568-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREOF | PIEZO1, ORAI2, VDAC2 | ALDH1A1 1275/4885MAPT 775/4885HPGD 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.